Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04136756 · ClinicalTrials.gov registry record · Phase 1
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT04136756 is a Phase 1 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT04136756, a Phase 1 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab. After determination of the recommended Phase 2 dose (RP2D) of NKTR-255, NKTR-255 will be evaluated in Part 2. During the Part 2 dose expansion portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab. This is a Phase 1 study to evaluate safety and tolerability of NKTR-255 alone and in combination with daratumumab or rituximab.
Interventions
- DRUG Rituximab
- DRUG Daratumumab
- DRUG NKTR-255
- DRUG NKTR-255 Q21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-10-07 |
| Est. Completion | 2023-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04136756
The ClinicalTrials.gov registry entry for NCT04136756 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rituximab is the first listed.
NCT04136756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04136756 about?
NCT04136756 is a clinical study titled "NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma". Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administe...
What is the current status of trial NCT04136756?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-10-07. Estimated completion is 2023-04-24.
What interventions are being tested in trial NCT04136756?
The interventions under investigation include: Rituximab (DRUG), Daratumumab (DRUG), NKTR-255 (DRUG), NKTR-255 Q21 (DRUG).
Who is sponsoring clinical trial NCT04136756?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.